
Sharmila Banerjee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5312310/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evolution of Tc-99m in diagnostic radiopharmaceuticals. Seminars in Nuclear Medicine, 2001, 31, 260-277.	4.6	212
2	Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications. Chemical Reviews, 2015, 115, 2934-2974.	47.7	203
3	<i>N</i> - <i>o</i> -Vanillylidene- <scp>l</scp> -histidine: Experimental Charge Density Analysis of a Double Zwitterionic Amino Acid Schiff-Base Compound. Crystal Growth and Design, 2010, 10, 1665-1676.	3.0	81
4	Comparative studies of 177Lu–EDTMP and 177Lu–DOTMP as potential agents for palliative radiotherapy of bone metastasis. Applied Radiation and Isotopes, 2008, 66, 1196-1205.	1.5	68
5	¹⁷⁷ Lu-EDTMP: A Viable Bone Pain Palliative in Skeletal Metastasis. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 202-213.	1.0	64
6	177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Applied Radiation and Isotopes, 2002, 57, 177-184.	1.5	61
7	Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nuclear Medicine and Biology, 2008, 35, 589-597.	0.6	58
8	A novel [99mTcN]2+ complex of metronidazole xanthate as a potential agent for targeting hypoxia. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3398-3401.	2.2	55
9	170Tm-EDTMP: a potential cost-effective alternative to 89SrCl2 for bone pain palliation. Nuclear Medicine and Biology, 2009, 36, 561-568.	0.6	55
10	Theranostic Applications of Lutetium-177 in Radionuclide Therapy. Current Radiopharmaceuticals, 2015, 9, 94-101.	0.8	52
11	Clinical utility of ¹⁷⁷ Luâ€DOTATATE PRRT in somatostatin receptorâ€positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity. Head and Neck, 2020, 42, 401-416.	2.0	50
12	Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nuclear Medicine Communications, 2006, 27, 661-668.	1.1	45
13	Therapeutic efficacy, prognostic variables and clinical outcome of ¹⁷⁷ Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-Ã-vis Gleason score in such cohort. British Journal of Radiology, 2019, 92, 20190380.	2.2	44
14	Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients. Clinical Nuclear Medicine, 2019, 44, e318-e322.	1.3	40
15	177Lu-EDTMP for Treatment of Bone Pain in Patients with Disseminated Skeletal Metastases. Journal of Nuclear Medicine Technology, 2014, 42, 55-61.	0.8	39
16	Evaluation of 99mTc(CO)3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia. Bioorganic and Medicinal Chemistry, 2006, 14, 7666-7670.	3.0	38
17	Development of a Radioimmunoassay Procedure for Aflatoxin B1Measurement. Journal of Agricultural and Food Chemistry, 2003, 51, 843-846.	5.2	37
18	175Yb labeled polyaminophosphonates as potential agents for bone pain palliation. Applied Radiation and Isotopes, 2004, 60, 635-642.	1.5	37

#	Article	IF	CITATIONS
19	On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5233-5237.	2.2	36
20	On the preparation of a therapeutic dose of 177Lu-labeled DOTA–TATE using indigenously produced 177Lu in medium flux reactor. Applied Radiation and Isotopes, 2007, 65, 301-308.	1.5	35
21	Surface modified silk fibroin nanoparticles for improved delivery of doxorubicin: Development, characterization, in-vitro studies. International Journal of Biological Macromolecules, 2020, 164, 2018-2027.	7.5	34
22	A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy. Nuclear Medicine and Biology, 2010, 37, 655-663.	0.6	32
23	Synthesis and evaluation of 2-, 4-, 5-substituted nitroimidazole-iminodiacetic acid-99mTc(CO)3 complexes to target hypoxic tumors. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 535-542.	1.0	30
24	Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. Radiochimica Acta, 2012, 100, 115-126.	1.2	30
25	99mTc-labeling of colchicine using [99mTc(CO)3(H2O)3]+ and [99mTcN]2+ core for the preparation of potential tumor-targeting agents. Bioorganic and Medicinal Chemistry, 2006, 14, 793-799.	3.0	28
26	Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorganic and Medicinal Chemistry, 2004, 12, 6077-6084.	3.0	27
27	177Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. Nuclear Medicine and Biology, 2004, 31, 753-759.	0.6	27
28	177Lu-DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis. Radiochimica Acta, 2008, 96, 55-61.	1.2	27
29	[186/188Re] rhenium-ethylene dicysteine (Re-Ec): preparation and evaluation for possible use in endovascular brachytherapy. Nuclear Medicine and Biology, 2000, 27, 189-197.	0.6	26
30	Tc-99m and Re-186 complexes of tetraphosphonate ligands and their biodistribution pattern in animal models. Nuclear Medicine and Biology, 2001, 28, 205-213.	0.6	26
31	On the structural modification of 2-nitroimidazole-99mTc(CO)3 complex, a hypoxia marker, for improving in vivo pharmacokinetics. Nuclear Medicine and Biology, 2012, 39, 1236-1242.	0.6	26
32	A study on nitroimidazole-99mTc(CO)3 complexes as hypoxia marker: Some observations towards possible improvement in in vivo efficacy. Nuclear Medicine and Biology, 2014, 41, 600-610.	0.6	26
33	Clinical translation of 177Lu-labeled PSMA-617: Initial experience in prostate cancer patients. Nuclear Medicine and Biology, 2016, 43, 296-302.	0.6	26
34	Preparation and bioevaluation of a 99mTc-labeled chlorambucil analog as a tumor targeting agent. Applied Radiation and Isotopes, 2009, 67, 1644-1649.	1.5	25
35	Biologic Evaluation of a Novel ¹⁸⁸ Re-Labeled Porphyrin in Mice Tumor Model. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 47-54.	1.0	25
36	99mTc-labeling studies of a modified metronidazole and its biodistribution in tumor bearing animal models. Nuclear Medicine and Biology, 2003, 30, 127-134.	0.6	24

#	Article	IF	CITATIONS
37	Convenient Preparation of [68Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy. Molecular Imaging and Biology, 2016, 18, 420-427.	2.6	23
38	Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons. Clinical and Experimental Metastasis, 2017, 34, 1-10.	3.3	23
39	⁶⁸ Gaâ€labeled Ciprofloxacin Conjugates as Radiotracers for Targeting Bacterial Infection. Chemical Biology and Drug Design, 2016, 87, 680-686.	3.2	22
40	A zwitterionic pH responsive ESIPT-Based fluorescence "Turn-On―Al3+ ion sensing probe and its bioimaging applications. Sensors and Actuators B: Chemical, 2017, 253, 1012-1025.	7.8	22
41	Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation. Nuclear Medicine Communications, 2004, 25, 1169-1176.	1.1	20
42	Preparation of Patient Doses of ¹⁷⁷ Lu-DOTA-TATE Using Indigenously Produced ¹⁷⁷ Lu: The Indian Experience. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 395-400.	1.0	19
43	Radiosynovectomy of Painful Synovitis of Knee Joints Due to Rheumatoid Arthritis by Intra-Articular Administration of 177 Lu-Labeled Hydroxyapatite Particulates: First Human Study and Initial Indian Experience. World Journal of Nuclear Medicine, 2015, 14, 81-88.	0.5	19
44	Radiochemical studies of 99mTc complexes of modified cysteine ligands and bifunctional chelating agents. Nuclear Medicine and Biology, 1999, 26, 555-561.	0.6	18
45	Potential 166Ho radiopharmaceuticals for intravascular radiation therapy (IVRT)-I : [166Ho] holmium labeled ethylene dicysteine. Nuclear Medicine and Biology, 2001, 28, 309-317.	0.6	18
46	166Ho-Labeled Hydroxyapatite Particles: A Possible Agent for Liver Cancer Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 7-14.	1.0	17
47	Preparation of ¹⁷⁷ Lu-Labeled Oxine in Lipiodol as a Possible Agent for Therapy of Hepatocellular Carcinoma: A Preliminary Animal Study. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 539-543.	1.0	17
48	Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷ Lu-EDTMP in Patients: Phase 0/I study. Current Radiopharmaceuticals, 2015, 9, 71-84.	0.8	17
49	Syntheses of potential spin probes for biomembranes - tempo and proxyl nitroxides of lithocholic acid. Tetrahedron, 1992, 48, 9939-9950.	1.9	16
50	An efficient and stereoselective synthesis of (2R,2′S)-1-O-(2′-hydroxyhexadecyl)glycerol and its oxo analogs: Potential antitumour compounds from Shark Liver Oil. Tetrahedron, 1996, 52, 6437-6452.	1.9	16
51	Synthesis and bio-evaluation of a new fatty acid derivative for myocardial imaging. Bioorganic and Medicinal Chemistry, 2008, 16, 7927-7931.	3.0	16
52	Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer. Nuclear Medicine Communications, 2009, 30, 362-367.	1.1	16
53	Synthesis and Biological Evaluation of ⁹⁰ Y-Labeled Porphyrin-DOTA Conjugate: A Potential Molecule for Targeted Tumor Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 651-656.	1.0	16
54	Formulation, Preclinical Evaluation, and Preliminary Clinical Investigation of an In-House Freeze-Dried EDTMP Kit Suitable for the Preparation of ¹⁷⁷ Lu-EDTMP. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 412-421.	1.0	16

#	Article	IF	CITATIONS
55	â€~4+1' Mixed Ligand Strategy for the Preparation of 99m Tc-Radiopharmaceuticals for Hypoxia Detecting Applications. ChemistrySelect, 2017, 2, 2910-2916.	1.5	16
56	An estradiol-conjugate for radiolabelling with 177Lu: an attempt to prepare a radiotherapeutic agent. Bioorganic and Medicinal Chemistry, 2005, 13, 4315-4322.	3.0	15
57	Synthesis and evaluation of ether containing 99mTc–nitrido dithiocarbamate complexes as brain perfusion imaging agent. Applied Radiation and Isotopes, 2006, 64, 361-367.	1.5	15
58	Preparation and bioevaluation of 99mTc-carbonyl complex of 5-hydroxy tryptamine derivative. Applied Radiation and Isotopes, 2006, 64, 888-892.	1.5	15
59	Radiolabeling, Stability Studies, and Pharmacokinetic Evaluation of Thulium-170-Labeled Acyclic and Cyclic Polyaminopolyphosphonic Acids. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 737-745.	1.0	15
60	Synthesis of 2'-(3α-benzyloxy-24-norcholan-23-yl)-2',4',4'-trimethyl- 4',5'-dihydrooxazoline-n-oxyl - a new potential spin probe for biomembranes. Tetrahedron, 1992, 48, 133-148.	1.9	14
61	Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application. Journal of Radioanalytical and Nuclear Chemistry, 2014, 299, 1389-1398.	1.5	14
62	Theranostic Treatment of Metastatic Bone Pain With 177Lu-DOTMP. Clinical Nuclear Medicine, 2016, 41, 966-967.	1.3	14
63	Modulation of in vivo distribution through chelator: Synthesis and evaluation of a 2-nitroimidazole–dipicolylamine–99mTc(CO)3 complex for detecting tumor hypoxia. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 46-50.	2.2	14
64	99mTcN complexes of tert-butyl dithiocarbamate and methoxyisobutyl dithiocarbamate as myocardial and brain imaging agents. Nuclear Medicine Communications, 2005, 26, 1013-1019.	1.1	13
65	Preparation and preliminary biological evaluation of a 177Lu labeled nitroimidazole derivative for possible use in targeted tumor therapy. Radiochimica Acta, 2006, 94, 375-380.	1.2	13
66	Preparation and preliminary bioevaluation of 99mTc(CO)3-11Î ² -progesterone derivative prepared via click chemistry route. Nuclear Medicine and Biology, 2010, 37, 997-1004.	0.6	13
67	A Freeze-Dried Kit for the Preparation of 188Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 139-144.	1.0	12
68	Production, separation and supply prospects of ⁶⁷ Cu with the development of fast neutron sources and photonuclear technology. Radiochimica Acta, 2018, 106, 549-557.	1.2	12
69	Formulation and evaluation of letrozole-loaded spray dried liposomes with PEs for topical application. Journal of Liposome Research, 2020, 30, 274-284.	3.3	12
70	Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 756-758.	6.4	12
71	Examining Absorbed Doses of Indigenously Developed ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 292-304.	1.0	12
72	Studies on the preparation and stability of samarium-153 propylene diamine tetramethylene phosphonate (PDTMP) complex as a bone seeker. Applied Radiation and Isotopes, 2000, 53, 987-991.	1.5	11

#	Article	IF	CITATIONS
73	186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation. Nuclear Medicine and Biology, 2001, 28, 709-717.	0.6	11
74	Preparation and <i>In-Vivo</i> Evaluation of ¹⁸⁸ Re(CO) ₃ -Colchicine Complex for Use as Tumor-Targeting Agent. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 741-748.	1.0	11
75	Synthesis and Preliminary Bioevaluation of ^{99m} Tc(CO) ₃ -17α-Triazolylandrost-4-Ene-3-One Derivative Prepared via Click Chemistry Route. Cancer Biotherapy and Radiopharmaceuticals, 2011, 26, 539-545.	1.0	11
76	Proxyl nitroxide of lithocholic acid: A potential spin probe for model membranes. Bioorganic and Medicinal Chemistry, 1993, 1, 341-347.	3.0	10
77	A novel 99mTc-labeled testosterone derivative as a potential agent for targeting androgen receptors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5788-5792.	2.2	10
78	A ^{99m} Tc-Labeled Misonidazole Analogue: Step Toward a ^{99m} Tc-Alternative to [¹⁸ F]Fluromisonidazole for Detecting Tumor Hypoxia. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 79-86.	1.0	10
79	Preparation of clinical-scale ¹⁷⁷ Lu-Rituximab: Optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 234-241.	1.0	10
80	¹⁰⁹ Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a Potential Agent for Targeted Tumor Therapy. Current Radiopharmaceuticals, 2012, 5, 340-347.	0.8	10
81	â€~Reverse discordance' between 68Ga-DOTA-NOC PET/CT and 177Lu-DOTA-TATE posttherapy scan. Nuclear Medicine Communications, 2011, 32, 654-658.	1.1	9
82	Radiosynthesis and Biological Evaluation of 68Ga-Labeled Colchicine Conjugates. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 251-256.	1.0	9
83	¹⁷⁷ Lu-labeled carbon nanospheres: a new entry in the field of targeted radionanomedicine. RSC Advances, 2016, 6, 50761-50769.	3.6	9
84	Juglone–ascorbic acid synergy inhibits metastasis and induces apoptotic cell death in poorly differentiated thyroid carcinoma by perturbing SOD and catalase activities. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22176.	3.0	9
85	Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model. Current Radiopharmaceuticals, 2011, 4, 150-160.	0.8	9
86	A novel concept of radiosynthesis of a 99mTc-labeled dimeric RGD peptide as a potential radiotracer for tumor imaging. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1808-1812.	2.2	8
87	Neutral 99mTc(CO)3 complexes of "clicked―nitroimidazoles for the detection of tumor hypoxia. Journal of Radioanalytical and Nuclear Chemistry, 2016, 307, 69-77.	1.5	8
88	¹⁷⁷ Luâ€ÐOTMP induces G2/M cell cycle arrest and apoptosis in MG63 cell line. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 837-846.	1.0	8
89	Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies. World Journal of Nuclear Medicine, 2018, 17, 228-235.	0.5	8
90	Serum prolactin in seizure disorders. Indian Pediatrics, 2004, 41, 827-31.	0.4	8

#	Article	IF	CITATIONS
91	On the synthesis, isolation, and radiochemical studies for the preparation of in-house kits for 99mTc-meso- and d,l-HMPAO: a few additional observations. Nuclear Medicine and Biology, 1999, 26, 327-338.	0.6	7
92	Syntheses and radiolabeling of cysteine-oximes and pharmacological behaviour of their 99mTc complexes. Applied Radiation and Isotopes, 2000, 52, 69-76.	1.5	7
93	Preparation of99mTc(CO)3-Carboxymethylthioethyl Iminodiacetic Acid and Evaluation as a Potential Renal Imaging Agent. Current Radiopharmaceuticals, 2012, 5, 65-70.	0.8	7
94	Preparation and evaluation of a 99mTcN–PNP complex of sanazole analogue for detecting tumor hypoxia. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1394-1397.	2.2	7
95	Synthesis and evaluation of a phenylbenzothiazole-based 99mTc(CO)3-radiotracer for possible application in imaging of β-amyloid plaques in Alzheimer's disease. Journal of Radioanalytical and Nuclear Chemistry, 2014, 302, 1339-1344.	1.5	7
96	Preparation and bioevaluation of [99mTcN]2+-labeled tetrameric complex of E-c(RGDfK)2 as a radiotracer for imaging αvβ3 integrins in tumors. Journal of Radioanalytical and Nuclear Chemistry, 2016, 309, 923.	1.5	7
97	Synthesis and evaluation of a novel 99mTcN(PNP)-complex with metronidazole isocyanide ligand as a marker for tumor hypoxia. Journal of Radioanalytical and Nuclear Chemistry, 2016, 308, 363-369.	1.5	7
98	Stereoselective total synthesis of (2R,2′S,3Z)-1-O-(2-methoxyhexadecenyl) glycerol and (2R,2′S)-1-(2′-methoxyhexadecyl)glycerol-potential antitumour compounds from Shark liver oil. Tetrahedron, 1995, 51, 4723-4732.	1.9	6
99	Evaluation of new positively charged 11―and 12â€carbon ^{99m} Tc″abeled fatty acid derivatives for myocardial imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2010, 53, 580-585.	1.0	6
100	Synthesis, radiolabeling and evaluation of a new positively charged ^{99m} Tc″abeled fatty acid derivative for myocardial imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 150-156.	1.0	6
101	Stereoselective synthesis of an iodinated resveratrol analog: Preliminary bioevaluation studies of the radioiodinated species. Applied Radiation and Isotopes, 2011, 69, 996-1001.	1.5	6
102	Preparation of Therapeutic Dose of ¹⁷⁷ Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with â€~In-situ' Preparation at Hospital Radiopharmacy. Current Radiopharmaceuticals, 2014, 7, 12-19.	0.8	6
103	Evaluation of ¹⁷⁷ Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy. Current Radiopharmaceuticals, 2015, 9, 64-70.	0.8	6
104	Synthesis and comparative <i>in vivo</i> evaluation of ^{99m} Tc(<scp>CO</scp>) ₃ â€labeled <scp>PEG</scp> ylated and nonâ€ <scp>PEG</scp> ylated <scp>cRGDfK</scp> peptide monomers. Chemical Biology and Drug Design, 2017, 89, 371-378.	3.2	6
105	Preparation and preliminary evaluation of a tris-metronidazole-99mTc(CO)3 complex for targeting tumor hypoxia. Journal of Radioanalytical and Nuclear Chemistry, 2018, 317, 1203-1210.	1.5	6
106	Potential immunomodulatory effect of allelochemical juglone in mice vaccinated with BCG. Toxicon, 2019, 157, 43-52.	1.6	6
107	Preparation and in vivo evaluation of 99mTcN-tertiary butyl xanthate as a potential myocardial agent. Applied Radiation and Isotopes, 2006, 64, 663-667.	1.5	5
108	Radiosynthesis and in vitro evaluation of 99mTc(CO)3-labeled folic acid derivative. Journal of Radioanalytical and Nuclear Chemistry, 2011, 290, 89-93.	1.5	5

#	Article	IF	CITATIONS
109	Effect of lipophilicity on biological properties of ¹⁰⁹ Pd-porphyrin complexes: a preliminary investigation. Journal of Porphyrins and Phthalocyanines, 2012, 16, 64-71.	0.8	5
110	Improved Kit Formulation for Preparation of ^{99m} Tc-HYNIC-TOC: Results of Preliminary Clinical Evaluation in Imaging Patients with Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 387-394.	1.0	5
111	Utility of99mTc-Hynic-TOC in 1311 Whole-Body Scan Negative Thyroid Cancer Patients with Elevated Serum Thyroglobulin Levels. World Journal of Nuclear Medicine, 2015, 14, 101.	0.5	5
112	Syntheses and biological evaluation of ^{99m} Tc-HYNIC-fatty acid complexes for myocardial imaging. RSC Advances, 2015, 5, 93374-93385.	3.6	5
113	Formulation and evaluation of freeze-dried DOTMP kit for the preparation of clinical-scale ¹⁷⁷ Lu-DOTMP and ¹⁵³ Sm-DOTMP at the hospital radiopharmacy. Radiochimica Acta, 2015, 103, 595-604.	1.2	5
114	In VitroEvaluation of188Re-HEDP: A Mechanistic View of Bone Pain Palliations. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 184-191.	1.0	5
115	Preparation and preliminary bioevaluation of 68Ga-oxine in lipiodol as a potential liver imaging agent. Journal of Radioanalytical and Nuclear Chemistry, 2017, 311, 263-268.	1.5	5
116	A compact solvent extraction based 99Mo/99 mTc generator for hospital radiopharmacy. Applied Radiation and Isotopes, 2019, 143, 41-46.	1.5	5
117	Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between) Tj ETQq1 1 0.7 disease course?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1793-1797.	784314 rg 6.4	ßT /Overloc
118	Technetium labeled doxorubicin loaded silk fibroin nanoparticles: Optimization, characterization and in vitro evaluation. Journal of Drug Delivery Science and Technology, 2020, 56, 101539.	3.0	5
119	Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects. World Journal of Nuclear Medicine, 2021, 20, 73-81.	0.5	5
120	Production, characterization and in-vitro applications of single-domain antibody against thyroglobulin selected from novel T7 phage display library. Journal of Immunological Methods, 2021, 492, 112990.	1.4	5
121	Preparation and preliminary biological evaluation of a 166Ho labeled polyazamacrocycle for possible use as an intravascular brachytherapy (IVBT) agent. Applied Radiation and Isotopes, 2006, 64, 462-469.	1.5	4
122	Preparation and biological studies of 125I-DOTA-TATE. Applied Radiation and Isotopes, 2007, 65, 687-690.	1.5	4
123	Synthesis and bioevaluation of a 177Lu-labeled unsymmetrical cationic porphyrin derivative as a tumor targeting agent. Journal of Radioanalytical and Nuclear Chemistry, 2016, 307, 1537-1544.	1.5	4
124	Radiochemical studies, pre-clinical investigation and preliminary clinical evaluation of 170 Tm-EDTMP prepared using in-house freeze-dried EDTMP kit. Applied Radiation and Isotopes, 2017, 122, 7-13.	1.5	4
125	Preparation and comparative evaluation of <scp> ^{99m}Tcâ€HYNICâ€eNGR and ^{99m}Tcâ€HYNICâ€PEG ₂â€eNGR </scp> as tumorâ€targeting molecular imaging probes. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 68-76.	1.0	4
126	The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results. Nuclear Medicine Communications, 2018, 39, 1061-1063.	1.1	4

#	Article	IF	CITATIONS
127	Formulation and radiochemical evaluation of a freeze-dried mixed peptide kit for the preparation of 68Ga-labeled peptides for PET imaging of somatostatin receptor positive neuroendocrine cancers. Journal of Radioanalytical and Nuclear Chemistry, 2014, 302, 1259-1264.	1.5	3
128	Sequential Duo–Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors. Clinical Nuclear Medicine, 2020, 45, 714-715.	1.3	3
129	Quercetin induces proteolysis of mesenchymal marker vimentin through activation of caspase-3, and decreases cancer stem cell population in human papillary thyroid cancer cell line Phytomedicine Plus, 2021, 1, 100108.	2.0	3
130	One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 178-211.	1.0	3
131	Synthesis of ^{99m} Tc-Nitrido Heterocomplex of Piperidine and <i>In Vitro</i> and <i>In Vivo</i> Evaluation of Its Affinity for Sigma Receptors. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 34-42.	1.0	2
132	Formulation of Patient Dose of 177Lu-DOTA-TATE in Hospital Radiopharmacy in India: Preparation Using In Situ Methodology Vis-a-Vis Freeze-Dried Kit. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 301-302.	1.0	2
133	Radiosynthesis and evaluation of a 99mTc-folic acid radiotracer prepared using [99mTcN(PNP)]2+ metal fragment. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1329-1332.	2.2	2
134	Developing a dedicated comprehensive α-radionuclide therapy program. Nuclear Medicine Communications, 2017, 38, 103-105.	1.1	2
135	170Tm-EDTMP. Clinical Nuclear Medicine, 2017, 42, 235-236.	1.3	2
136	Novel radioassay for anti-thyroperoxidase autoantibodies using protein A coupled magnetizable cellulose particles as an immunoadsorbent. Journal of Radioanalytical and Nuclear Chemistry, 2020, 323, 1041-1046.	1.5	2
137	On the Separation of Yttrium-90 from High-Level Liquid Waste: Purification to Clinical-Grade Radiochemical Precursor, Clinical Translation in Formulation of 90Y-DOTATATE Patient Dose. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 143-159.	1.0	2
138	Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy. Cancer Biotherapy and Radiopharmaceuticals, 2021, 36, 682-692.	1.0	2
139	Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use Lu-DOTA-TATE: The Intricate Radiochemistry Aspects. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 266-273.	1.0	2
140	Clinical Efficacy of Sodium [99mTc] Pertechnetate from Low Specific Activity 99Mo/99mTc Autosolex Generator in Hospital Radiopharmacy Centre. Nuclear Medicine Review, 2020, 23, 1-14.	0.5	2
141	Clinical Dose Preparation of [¹⁷⁷ Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷ Lu]LuCl ₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 384-402.	1.0	2
142	Single vial freeze-dried TRODAT-1 kit: Preparation and demonstration of clinical efficacy of [99m Tc]TRODAT-1 in Indian scenario. Applied Radiation and Isotopes, 2015, 96, 57-62.	1.5	1
143	Microarray immunoassay for thyrotropin on track-etched membranes using radiotracers. Journal of Radioanalytical and Nuclear Chemistry, 2019, 322, 99-104.	1.5	1
144	Purification of 99Mo and 99mTc from radioactive traces of Nb, Zr, and Y impurities: method applicable in the purification of the spent 100/99Mo–99mTc generator. Journal of Radioanalytical and Nuclear Chemistry, 2019, 322, 809-815.	1.5	1

#	Article	IF	CITATIONS
145	Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours. Asia Oceania Journal of Nuclear Medicine and Biology, 2014, 2, 30-41.	0.1	1
146	Estimation of Absorbed Doses of Indigenously Produced "Direct-route― Lutetium-177-[¹⁷⁷ Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [¹⁷⁷ Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles. Cancer Biotherapy and	1.0	1
147	Radiopharmaceuticals, 2022, 37, 214-225 Automated Radiochemical Synthesis of Pharmaceutical Grade [¹⁸ F]FLT using 3â€Nâ€Bocâ€5'â€Oâ€dimethoxytritylâ€3'â€Oâ€nosylâ€thymidine precursor and its Sepâ€Pak® Purifica Selective Elution from Reversed Phase. Journal of Labelled Compounds and Radiopharmaceuticals, 2022,	tion empl 1.0	oying
148	Preparation and Evaluation of 99mTc(CO)3-Labeled Pentadecanoic Acid Derivative and Its Suspension in Lipiodol. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 503-507.	1.0	0
149	Formulation of clinical-scale 177 Lu-PSMA-617: From laboratory to clinics. Nuclear Medicine and Biology, 2016, 43, 836.	0.6	0
150	Synthesis of O-(1â€2-[18F]fluoropropan-2â€2-yl)-l-tyrosine (1-[18F]FPT) via Ni(II) complex of (S) tyrosine schiff‹ base precursor. Journal of Radioanalytical and Nuclear Chemistry, 2017, 314, 483-490.	^M S 1.5	0
151	Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. Journal of Nuclear Medicine Technology, 2019, 47, 292-299.	0.8	0
152	Clinical efficacy of Sep-Pak® assisted one pot automated synthesis of pharmaceutical grade [18F]FLT using 5′-O-(benzoyl)-2,3′-anhydrothymidine precursor. Journal of Radioanalytical and Nuclear Chemistry, 2021, 327, 585-596.	1.5	0
153	On the production of pharmaceutical grade indium-111-chloride in the medical cyclotron from natural cadmium target and its use in formulation of diagnostic patient dose of 111In-pentetreotide for imaging somatostatin receptor overexpression. Journal of Radioanalytical and Nuclear Chemistry, 2021, 328, 835-846.	1.5	0
154	Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity. Nuclear Medicine Communications, 2021, 42, 1076-1084.	1.1	0
155	Evaluation of Different Methods for the Detection of Anti- Thyroglobulin Autoantibody: Prevalence of Anti-Thyroglobulin Autoantibody and Anti-Microsomal Autoantibody in Thyroid Cancer Patients. Indian Journal of Clinical Biochemistry, 0, , 1.	1.9	0